Cubist Systematic Strategies, LLC Clearside Biomedical, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.2 - $2.02 $29,484 - $49,631	24,570 New	24,570 $37,000
Q2 2022 Aug 15, 2022	SELL	$1.3 - $2.49 $24,960 - $47,808	-19,200 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.35 - $2.88 $45,558 - $97,191	-33,747 Reduced 63.74%	19,200 $44,000
Q4 2021 Feb 14, 2022	SELL	$2.72 - $5.72 $73,494 - $154,554	-27,020 Reduced 33.79%	52,947 $146,000
Q3 2021 Nov 15, 2021	BUY	$4.83 - $7.2 $257,492 - $383,839	53,311 Added 200.0%	79,967 $480,000
Q2 2021 Aug 16, 2021	BUY	$2.32 - $5.38 $14,049 - $32,581	6,056 Added 29.4%	26,656 $130,000
Q1 2021 May 17, 2021	BUY	$2.24 - $4.25 $46,144 - $87,550	20,600 New	20,600 $51,000
Q4 2018 Feb 14, 2019	SELL	$1.0 - $6.12 $8,599 - $52,625	-8,599 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$6.03 - $11.24 $49,439 - $92,156	8,199 Added 2049.75%	8,599 $53,000
Q2 2018 Aug 14, 2018	SELL	$8.91 - $14.54 $105,770 - $172,604	-11,871 Reduced 96.74%	400 $4,000
Q1 2018 May 15, 2018	BUY	$5.57 - $14.28 $68,349 - $175,229	12,271 New	12,271 $132,000

13.4M

17.6K

100

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $61.4M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.